| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MEG9 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 3.896536361 | Upregulation | 0 | student's t test | 2020 | 32416070 | |
| MEG9 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 2.851300315 | Upregulation | 3.54E-13 | student's t test | 2020 | 32416070 | |
| MEG9 | Enterovirus D68 (Fermon strain of EV-D68) | MOI = 1 ;
24 hr |
RD Human embryonal rhabdomyosarcoma cells | qPCR | 0.391228405 | Downregulation | p < 0.05 | cufflinks | two-sample t-test | 2021 | 34743709 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose